On May 15, 2025, the "2024 China Healthcare & Big Health Industry Investment and Financing Honor Roll" was officially announced. Yinjia Bio was honored to be listed among the "Top 50 Most Investable Healthcare Companies of 2024," recognized for its innovative R&D capabilities, forward-looking strategic planning, and industry-leading practices. This marks the company's second time receiving this award since 2022, demonstrating Yinjia Bio's comprehensive competitiveness and sustainable development potential in the biomedical and healthcare field.
As a witness and contributor to China's healthcare industry development, the annual list of Most Investable Healthcare Companies has become a key benchmark for measuring a company's overall strength. Yinjia Bio sincerely appreciates the long-term trust and support from CITIC Securities CHC. This honor not only affirms our past technological achievements but also serves as a driving force and motivation for our continued rapid growth.
In recent years, the biopharmaceutical industry has faced dual challenges from the pandemic's impact and deep industry adjustments. Amidst post-pandemic economic shifts and uncertainties, market volatility, and investment contraction pressures, Yinjia Bio has forged ahead against the trend. Adhering to the belief that "innovation builds core competitiveness," we have intensified technological R&D and product iteration. By collaborating with upstream and downstream partners on joint technological breakthroughs and capacity synergy, we are building a resilient, integrated R&D, production, and sales ecosystem to accelerate our development.
Dr. Wu Yifei, founder of Yinjia Bio, stated: "We are deeply honored to receive this prestigious award twice within three years. This recognition carries the expectations and encouragement of our industry peers. Moving forward, we will stay true to our original aspirations, continue to strengthen our foundation through 'technological depth,' expand our boundaries via 'ecosystem co-creation,' and uphold the philosophy of 'symbiosis and shared success.' We are committed to providing a reliable 'trusted choice' for global life science research and novel medical development."
Prev